Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 302

1.

A Combination Of Approved Antibodies Overcomes Resistance Of Lung Cancer To Osimertinib By Blocking Bypass Pathways.

Romaniello D, Mazzeo L, Mancini M, Marrocco I, Noronha A, Kreitman MS, Srivastava S, Ghosh S, Lindzen M, Salame TM, Onn A, Bar J, Yarden Y.

Clin Cancer Res. 2018 Jul 2. pii: clincanres.0450.2018. doi: 10.1158/1078-0432.CCR-18-0450. [Epub ahead of print]

PMID:
29967248
2.

Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features.

Arandkar S, Furth N, Elisha Y, Nataraj NB, van der Kuip H, Yarden Y, Aulitzky W, Ulitsky I, Geiger B, Oren M.

Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):6410-6415. doi: 10.1073/pnas.1719076115. Epub 2018 Jun 4.

PMID:
29866855
3.

Irreversible modifications of receptor tyrosine kinases.

Kreitman M, Noronha A, Yarden Y.

FEBS Lett. 2018 May 22. doi: 10.1002/1873-3468.13095. [Epub ahead of print]

PMID:
29790151
4.

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface.

Claus J, Patel G, Autore F, Colomba A, Weitsman G, Soliman TN, Roberts S, Zanetti-Domingues LC, Hirsch M, Collu F, George R, Ortiz-Zapater E, Barber PR, Vojnovic B, Yarden Y, Martin-Fernandez ML, Cameron A, Fraternali F, Ng T, Parker PJ.

Elife. 2018 May 1;7. pii: e32271. doi: 10.7554/eLife.32271.

5.

SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors.

Roth L, Srivastava S, Lindzen M, Sas-Chen A, Sheffer M, Lauriola M, Enuka Y, Noronha A, Mancini M, Lavi S, Tarcic G, Pines G, Nevo N, Heyman O, Ziv T, Rueda OM, Gnocchi D, Pikarsky E, Admon A, Caldas C, Yarden Y.

Sci Signal. 2018 Jan 30;11(515). pii: eaan0949. doi: 10.1126/scisignal.aan0949.

PMID:
29382783
6.

An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.

Mancini M, Gal H, Gaborit N, Mazzeo L, Romaniello D, Salame TM, Lindzen M, Mahlknecht G, Enuka Y, Burton DG, Roth L, Noronha A, Marrocco I, Adreka D, Altstadter RE, Bousquet E, Downward J, Maraver A, Krizhanovsky V, Yarden Y.

EMBO Mol Med. 2018 Feb;10(2):294-308. doi: 10.15252/emmm.201708076.

7.

MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: the hOrmone and Diet in the ETiology of breast cancer prospective study.

Muti P, Donzelli S, Sacconi A, Hossain A, Ganci F, Frixa T, Sieri S, Krogh V, Berrino F, Biagioni F, Strano S, Beyene J, Yarden Y, Blandino G.

Carcinogenesis. 2018 Feb 9;39(2):98-108. doi: 10.1093/carcin/bgx126.

PMID:
29126102
8.

Corrigendum: The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.

Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N, Raver-Shapira N, Minsky N, Pirngruber J, Tarcic G, Hublarova P, Moyal L, Gana-Weisz M, Shiloh Y, Yarden Y, Johnsen SA, Vojtesek B, Berger SL, Oren M.

Genes Dev. 2017 Sep 15;31(18):1926. doi: 10.1101/gad.307207.117. No abstract available.

9.

Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone.

Enuka Y, Feldman ME, Chowdhury A, Srivastava S, Lindzen M, Sas-Chen A, Massart R, Cheishvili D, Suderman MJ, Zaltsman Y, Mazza CA, Shukla K, Körner C, Furth N, Lauriola M, Oren M, Wiemann S, Szyf M, Yarden Y.

Nucleic Acids Res. 2017 Dec 15;45(22):12681-12699. doi: 10.1093/nar/gkx865.

10.

CRISPR-assisted receptor deletion reveals distinct roles for ERBB2 and ERBB3 in skin keratinocytes.

Dahlhoff M, Gaborit N, Bultmann S, Leonhardt H, Yarden Y, Schneider MR.

FEBS J. 2017 Oct;284(19):3339-3349. doi: 10.1111/febs.14196. Epub 2017 Sep 14.

PMID:
28805349
11.

Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant disease.

Golan T, Stossel C, Schvimer M, Atias D, Halperin S, Buzhor E, Raitses-Gurevich M, Cohen K, Pri-Chen S, Wilson J, Denroche RE, Lungu I, Bartlett JMS, Mbabaali F, Yarden Y, Nataraj NB, Gallinger S, Berger R.

Oncotarget. 2017 Jun 20;8(25):40778-40790. doi: 10.18632/oncotarget.17253.

12.

Coordinated Pulses of mRNA and of Protein Translation or Degradation Produce EGF-Induced Protein Bursts.

Golan-Lavi R, Giacomelli C, Fuks G, Zeisel A, Sonntag J, Sinha S, Köstler W, Wiemann S, Korf U, Yarden Y, Domany E.

Cell Rep. 2017 Mar 28;18(13):3129-3142. doi: 10.1016/j.celrep.2017.03.014.

13.

Database-independent Protein Sequencing (DiPS) Enables Full-length de Novo Protein and Antibody Sequence Determination.

Savidor A, Barzilay R, Elinger D, Yarden Y, Lindzen M, Gabashvili A, Adiv Tal O, Levin Y.

Mol Cell Proteomics. 2017 Jun;16(6):1151-1161. doi: 10.1074/mcp.O116.065417. Epub 2017 Mar 27.

14.

The short and the long: non-coding RNAs and growth factors in cancer progression.

Sas-Chen A, Srivastava S, Yarden Y.

Biochem Soc Trans. 2017 Feb 8;45(1):51-64. doi: 10.1042/BST20160131. Review.

PMID:
28202659
15.

RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer.

Tarcic O, Granit RZ, Pateras IS, Masury H, Maly B, Zwang Y, Yarden Y, Gorgoulis VG, Pikarsky E, Ben-Porath I, Oren M.

Cell Death Differ. 2017 Apr;24(4):694-704. doi: 10.1038/cdd.2016.126. Epub 2017 Feb 3.

16.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

17.

A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.

Gelfo V, Rodia MT, Pucci M, Dall'Ora M, Santi S, Solmi R, Roth L, Lindzen M, Bonafè M, Bertotti A, Caramelli E, Lollini PL, Trusolino L, Yarden Y, D'Uva G, Lauriola M.

Oncotarget. 2016 Nov 1;7(44):72167-72183. doi: 10.18632/oncotarget.12354.

18.

P2.42: An Immunotherapy Approach to Overcoming Resistance to Second and Third Generation EGFR Inhibitors: Track: Immunotherapy.

Yarden Y.

J Thorac Oncol. 2016 Oct;11(10S):S243-S244. doi: 10.1016/j.jtho.2016.08.113. Epub 2016 Sep 22. No abstract available.

19.

Interfering with the Dimerization of the ErbB Receptors by Transmembrane Domain-Derived Peptides Inhibits Tumorigenic Growth in Vitro and in Vivo.

Bublil EM, Cohen T, Arnusch CJ, Peleg A, Pines G, Lavi S, Yarden Y, Shai Y.

Biochemistry. 2016 Oct 4;55(39):5520-5530. Epub 2016 Sep 19.

PMID:
27575020
20.

LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer.

Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, Polycarpou-Schwarz M, Lavi S, Nevo N, Kuznetsov Y, Yuan J, Azuaje F; Oslo Breast Cancer Research Consortium (OSBREAC)SauerTorillGeislerJürgenHofvindSolveigBathenTone FBorgenElinEngebråtenOlavFodstadØysteinGarredØysteinGeitvikGry AarumKåresenRolfNaumeBjørnMælandsmoGunhild MariRussnesHege GSchlichtingEllenSørlieThereseLingjærdeOle ChristianSahlbergKristine KleiviSkjervenHelle KristineFritzmanBritt, Ulitsky I, Diederichs S, Wiemann S, Yakhini Z, Kristensen VN, Børresen-Dale AL, Yarden Y.

EMBO Mol Med. 2016 Sep 1;8(9):1052-64. doi: 10.15252/emmm.201606198. Print 2016 Sep.

22.

Tumor Cell Invasion Can Be Blocked by Modulators of Collagen Fibril Alignment That Control Assembly of the Extracellular Matrix.

Grossman M, Ben-Chetrit N, Zhuravlev A, Afik R, Bassat E, Solomonov I, Yarden Y, Sagi I.

Cancer Res. 2016 Jul 15;76(14):4249-58. doi: 10.1158/0008-5472.CAN-15-2813. Epub 2016 May 24.

23.

Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy.

Beyar-Katz O, Magidey K, Ben-Tsedek N, Alishekevitz D, Timaner M, Miller V, Lindzen M, Yarden Y, Avivi I, Shaked Y.

J Pathol. 2016 Jul;239(3):262-73. doi: 10.1002/path.4723. Epub 2016 Apr 29.

PMID:
27037906
24.

Feedback regulation of biological networks: Examples relevant to signalling pathways and resistance to pharmacological interceptors.

Yarden Y, Wheeler DL.

Semin Cell Dev Biol. 2016 Feb;50:83-4. doi: 10.1016/j.semcdb.2016.02.016. No abstract available.

PMID:
26940064
25.

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings.

Wilson S, Tod M, Ouerdani A, Emde A, Yarden Y, Adda Berkane A, Kassour S, Wei MX, Freyer G, You B, Grenier E, Ribba B.

CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):720-7. doi: 10.1002/psp4.12045. Epub 2015 Dec 11.

26.

Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.

Carvalho S, Levi-Schaffer F, Sela M, Yarden Y.

Br J Pharmacol. 2016 May;173(9):1407-24. doi: 10.1111/bph.13450. Epub 2016 Mar 14. Review.

27.

MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer.

Donzelli S, Cioce M, Muti P, Strano S, Yarden Y, Blandino G.

Semin Cell Dev Biol. 2016 Feb;50:133-42. doi: 10.1016/j.semcdb.2015.12.020. Epub 2016 Jan 7. Review.

PMID:
26773212
28.

Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor.

Enuka Y, Lauriola M, Feldman ME, Sas-Chen A, Ulitsky I, Yarden Y.

Nucleic Acids Res. 2016 Feb 18;44(3):1370-83. doi: 10.1093/nar/gkv1367. Epub 2015 Dec 10.

29.

Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.

Gaborit N, Lindzen M, Yarden Y.

Hum Vaccin Immunother. 2016 Mar 3;12(3):576-92. doi: 10.1080/21645515.2015.1102809. Epub 2015 Nov 3. Review.

30.

Epigenetic silencing of miR-145-5p contributes to brain metastasis.

Donzelli S, Mori F, Bellissimo T, Sacconi A, Casini B, Frixa T, Roscilli G, Aurisicchio L, Facciolo F, Pompili A, Carosi MA, Pescarmona E, Segatto O, Pond G, Muti P, Telera S, Strano S, Yarden Y, Blandino G.

Oncotarget. 2015 Nov 3;6(34):35183-201. doi: 10.18632/oncotarget.5930.

31.

The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors.

Schneider MR, Yarden Y.

Oncogene. 2016 Jun 9;35(23):2949-60. doi: 10.1038/onc.2015.372. Epub 2015 Oct 5. Review.

32.

Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.

Mancini M, Yarden Y.

Semin Cell Dev Biol. 2016 Feb;50:164-76. doi: 10.1016/j.semcdb.2015.09.018. Epub 2015 Sep 30. Review.

PMID:
26428295
33.

MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression.

Kedmi M, Sas-Chen A, Yarden Y.

J Clin Med. 2015 Aug 13;4(8):1578-99. doi: 10.3390/jcm4081578. Review.

34.

Multimerization of ERBB2/HER2 specific aptamer leads to improved receptor binding.

Mahlknecht G, Maron R, Schechter B, Yarden Y, Sela M.

Biochem Biophys Res Commun. 2015 Sep 18;465(2):218-24. doi: 10.1016/j.bbrc.2015.07.157. Epub 2015 Aug 4.

PMID:
26248137
35.

ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.

Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE.

Cancer Res. 2015 Sep 1;75(17):3554-67. doi: 10.1158/0008-5472.CAN-14-2959. Epub 2015 Jul 23.

36.

Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy.

Mahlknecht G, Sela M, Yarden Y.

Methods Mol Biol. 2015;1317:3-15. doi: 10.1007/978-1-4939-2727-2_1.

PMID:
26072398
37.

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.

Mancini M, Gaborit N, Lindzen M, Salame TM, Dall'Ora M, Sevilla-Sharon M, Abdul-Hai A, Downward J, Yarden Y.

Sci Signal. 2015 Jun 2;8(379):ra53. doi: 10.1126/scisignal.aaa0725.

PMID:
26038598
38.

Cancer Immunotherapy: More Is (Much) Better.

Yarden Y, Sela M.

Clin Cancer Res. 2015 Sep 15;21(18):4030-2. doi: 10.1158/1078-0432.CCR-15-0996. Epub 2015 May 27.

39.

An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors.

Carvalho S, Lindzen M, Lauriola M, Shirazi N, Sinha S, Abdul-Hai A, Levanon K, Korach J, Barshack I, Cohen Y, Onn A, Mills G, Yarden Y.

Oncogene. 2016 Jan 28;35(4):438-47. doi: 10.1038/onc.2015.93. Epub 2015 Apr 27.

PMID:
25915843
40.

ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.

D'Uva G, Aharonov A, Lauriola M, Kain D, Yahalom-Ronen Y, Carvalho S, Weisinger K, Bassat E, Rajchman D, Yifa O, Lysenko M, Konfino T, Hegesh J, Brenner O, Neeman M, Yarden Y, Leor J, Sarig R, Harvey RP, Tzahor E.

Nat Cell Biol. 2015 May;17(5):627-38. doi: 10.1038/ncb3149. Epub 2015 Apr 6.

PMID:
25848746
41.

EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer.

Kedmi M, Ben-Chetrit N, Körner C, Mancini M, Ben-Moshe NB, Lauriola M, Lavi S, Biagioni F, Carvalho S, Cohen-Dvashi H, Schmitt F, Wiemann S, Blandino G, Yarden Y.

Sci Signal. 2015 Mar 17;8(368):ra29. doi: 10.1126/scisignal.2005866.

PMID:
25783158
42.

Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression.

Cohen-Dvashi H, Ben-Chetrit N, Russell R, Carvalho S, Lauriola M, Nisani S, Mancini M, Nataraj N, Kedmi M, Roth L, Köstler W, Zeisel A, Yitzhaky A, Zylberg J, Tarcic G, Eilam R, Wigelman Y, Will R, Lavi S, Porat Z, Wiemann S, Ricardo S, Schmitt F, Caldas C, Yarden Y.

EMBO Mol Med. 2015 Mar;7(3):299-314. doi: 10.15252/emmm.201404134.

43.

Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer.

Ben-Chetrit N, Chetrit D, Russell R, Körner C, Mancini M, Abdul-Hai A, Itkin T, Carvalho S, Cohen-Dvashi H, Koestler WJ, Shukla K, Lindzen M, Kedmi M, Lauriola M, Shulman Z, Barr H, Seger D, Ferraro DA, Pareja F, Gil-Henn H, Lapidot T, Alon R, Milanezi F, Symons M, Ben-Hamo R, Efroni S, Schmitt F, Wiemann S, Caldas C, Ehrlich M, Yarden Y.

Sci Signal. 2015 Jan 20;8(360):ra7. doi: 10.1126/scisignal.2005537.

PMID:
25605973
44.

Examination of HER3 targeting in cancer using monoclonal antibodies.

Gaborit N, Abdul-Hai A, Mancini M, Lindzen M, Lavi S, Leitner O, Mounier L, Chentouf M, Dunoyer S, Ghosh M, Larbouret C, Chardès T, Bazin H, Pèlegrin A, Sela M, Yarden Y.

Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):839-44. doi: 10.1073/pnas.1423645112. Epub 2015 Jan 6.

45.

Basic cancer research: why it is essential for the future of cancer therapy.

Yarden Y, Caldes C.

Bull Cancer. 2014 Sep;101(9):E25-6. doi: 10.1684/bdc.2014.2024.

PMID:
25295602
46.

Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment.

Lauriola M, Enuka Y, Zeisel A, D'Uva G, Roth L, Sharon-Sevilla M, Lindzen M, Sharma K, Nevo N, Feldman M, Carvalho S, Cohen-Dvashi H, Kedmi M, Ben-Chetrit N, Chen A, Solmi R, Wiemann S, Schmitt F, Domany E, Yarden Y.

Nat Commun. 2014 Oct 3;5:5073. doi: 10.1038/ncomms6073.

47.

The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.

Kiuchi T, Ortiz-Zapater E, Monypenny J, Matthews DR, Nguyen LK, Barbeau J, Coban O, Lawler K, Burford B, Rolfe DJ, de Rinaldis E, Dafou D, Simpson MA, Woodman N, Pinder S, Gillett CE, Devauges V, Poland SP, Fruhwirth G, Marra P, Boersma YL, Plückthun A, Gullick WJ, Yarden Y, Santis G, Winn M, Kholodenko BN, Martin-Fernandez ML, Parker P, Tutt A, Ameer-Beg SM, Ng T.

Sci Signal. 2014 Aug 19;7(339):ra78. doi: 10.1126/scisignal.2005157.

PMID:
25140053
48.

Downregulation of microRNAs 145-3p and 145-5p is a long-term predictor of postmenopausal breast cancer risk: The ORDET prospective study.

Muti P, Sacconi A, Hossain A, Donzelli S, Ben Moshe NB, Ganci F, Sieri S, Krogh V, Berrino F, Biagioni F, Strano S, Beyene J, Yarden Y, Blandino G.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2471-81. doi: 10.1158/1055-9965.EPI-14-0398. Epub 2014 Jul 29.

49.

Steering tumor progression through the transcriptional response to growth factors and stroma.

Feldman ME, Yarden Y.

FEBS Lett. 2014 Aug 1;588(15):2407-14. doi: 10.1016/j.febslet.2014.05.036. Epub 2014 May 27. Review.

50.

Tumor suppressor microRNAs: a novel non-coding alliance against cancer.

Blandino G, Fazi F, Donzelli S, Kedmi M, Sas-Chen A, Muti P, Strano S, Yarden Y.

FEBS Lett. 2014 Aug 19;588(16):2639-52. doi: 10.1016/j.febslet.2014.03.033. Epub 2014 Mar 26. Review.

Supplemental Content

Loading ...
Support Center